Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

 
• By Emily Hayes

AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.

Business man showing pie chart in color background

More from Earnings

More from Business